New Drugs Of Psoriasis Treatment - Tofacitinib
Although many traditional systemic drugs or biological agents are available for the treatment of psoriasis, there is an unmet medical need for this disease. Recently, Dr. Yiu ZZN from the University of Manchester in England introduced the new oral psoriasis therapy approved or still under development. The review, published in Am J Clin Dermatol, is summarized as follows:
Tofacitinib, a Janus kinase (JAK) -1 and JAK3 inhibitor, is approved by the FDA for the treatment of rheumatoid arthritis.
A phase III RCT confirmed that tofacitinib (10 mg bid) for 12 weeks was noninferior to etanercept in psoriatic lesions and two phase III RCTs showed tofacitinib (5 or 10 mg bid) for 16 weeks was superior to placebo. There is no evidence of efficacy of tofacitinib in the treatment of PsA.
Common adverse reactions to tofacitinib are hemoglobin, neutrophil count, a low LDL / HDL ratio, and elevated creatine phosphokinase.
Tofatinib is particularly suitable for patients who can not receive injection therapy. Among patients who have failed traditional systemic therapies, tofacitinib may also be considered as a replacement for biologics based on a cost-effectiveness assessment.
The main adverse reactions associated with tofacitinib are dizziness, headache, gastrointestinal reactions (nausea, diarrhea), nasopharyngitis, and infections (especially respiratory and urinary tract infections) leading to neutropenia, low density and high Density lipoprotein and cholesterol levels, gastrointestinal disorders and infection of which the most common. The most common adverse reactions to laboratory tests are elevated creatinine and transaminase, hemoglobin and neutropenia.